- optionMONSTER•23 hours ago
A large trade is looking for more gains in Ionis Pharmaceuticals, which has skyrocketed in recent months. optionMONSTER's market scanner shows that 3,578 October 35 calls sold for $2.60 and 3,578 October ...
- Zacks•4 days ago
Ionis' (IONS) partner, Biogen (BIIB) has completed the rolling submission of an NDA for nusinersen for the treatment of spinal muscular atrophy.
- Market Realist•11 days ago
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
Ionis Pharmaceuticals, Inc (ISIS)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
At close: 4:00 PM EST
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|